These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 11862382

  • 21. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
    De Lerma Barbaro A, Procopio FA, Mortara L, Tosi G, Accolla RS.
    Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
    [Abstract] [Full Text] [Related]

  • 22. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
    Xu Y, McDonald J, Perloff E, Butticè G, Schreiber BM, Smith BD.
    Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
    [Abstract] [Full Text] [Related]

  • 23. Alport syndrome. Molecular genetic aspects.
    Hertz JM.
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [Abstract] [Full Text] [Related]

  • 24. Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA).
    Patarroyo JC, Stuve O, Piskurich JF, Hauser SL, Oksenberg JR, Zamvil SS.
    Genes Immun; 2002 Feb; 3(1):34-7. PubMed ID: 11857059
    [Abstract] [Full Text] [Related]

  • 25. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
    Broxmeyer HE, Cooper S, Hangoc G, Chang CH.
    Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
    [Abstract] [Full Text] [Related]

  • 26. Direct genetic correction as a new method for diagnosis and molecular characterization of MHC class II deficiency.
    Matheux F, Ikinciogullari A, Zapata DA, Barras E, Zufferey M, Dogu F, Regueiro JR, Reith W, Villard J.
    Mol Ther; 2002 Dec; 6(6):824-9. PubMed ID: 12498778
    [Abstract] [Full Text] [Related]

  • 27. Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activity of DCs.
    Märten A, Ziske C, Schöttker B, Weineck S, Renoth S, Buttgereit P, Schakowski F, König S, von Rücker A, Allera A, Schroers R, Sauerbruch T, Wittig B, Schmidt-Wolf IG.
    Cancer Gene Ther; 2001 Mar; 8(3):211-9. PubMed ID: 11332992
    [Abstract] [Full Text] [Related]

  • 28. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.
    Shi B, Vinyals A, Alia P, Broceño C, Chen F, Adrover M, Gelpi C, Price JE, Fabra A.
    Int J Biochem Cell Biol; 2006 Mar; 38(4):544-62. PubMed ID: 16343978
    [Abstract] [Full Text] [Related]

  • 29. Single nucleotide polymorphisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus.
    Koizumi K, Okamoto H, Iikuni N, Nakamura T, Kawamoto M, Momohara S, Ichikawa N, Furuya T, Kotake S, Taniguchi A, Yamanaka H, Kamatani N.
    Ann Rheum Dis; 2005 Jun; 64(6):947-50. PubMed ID: 15897313
    [Abstract] [Full Text] [Related]

  • 30. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
    Meissner M, Whiteside TL, Kaufmann R, Seliger B.
    Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
    [Abstract] [Full Text] [Related]

  • 31. Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease.
    Krawczyk M, Reith W.
    Tissue Antigens; 2006 Mar; 67(3):183-97. PubMed ID: 16573555
    [Abstract] [Full Text] [Related]

  • 32. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA.
    Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V.
    Eur J Immunol; 2003 Aug; 33(8):2337-47. PubMed ID: 12884309
    [Abstract] [Full Text] [Related]

  • 33. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.
    LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W.
    Eur J Immunol; 2004 Jun; 34(6):1513-25. PubMed ID: 15162420
    [Abstract] [Full Text] [Related]

  • 34. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
    Wiszniewski W, Fondaneche MC, Louise-Plence P, Prochnicka-Chalufour A, Selz F, Picard C, Le Deist F, Eliaou JF, Fischer A, Lisowska-Grospierre B.
    Immunogenetics; 2003 Feb; 54(11):747-55. PubMed ID: 12618906
    [Abstract] [Full Text] [Related]

  • 35. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M, Whiteside TL, van Kuik-Romein P, Valesky EM, van den Elsen PJ, Kaufmann R, Seliger B.
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [Abstract] [Full Text] [Related]

  • 36. Combined immunodeficiency with defective expression in MHC class II genes.
    Griscelli C, Lisowska-Grospierre B, Mach B.
    Immunodefic Rev; 1989 May; 1(2):135-53. PubMed ID: 2517209
    [Abstract] [Full Text] [Related]

  • 37. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
    Hake SB, Masternak K, Kammerbauer C, Janzen C, Reith W, Steimle V.
    Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
    [Abstract] [Full Text] [Related]

  • 38. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
    Zhou D, Masri S, Ye JJ, Chen S.
    Gene; 2005 Nov 21; 361():89-100. PubMed ID: 16181749
    [Abstract] [Full Text] [Related]

  • 39. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
    Arancibia-Cárcamo CV, Osawa H, Arnett HA, Háskova Z, George AJ, Ono SJ, Ting JP, Streilein JW.
    Eur J Immunol; 2004 Feb 21; 34(2):471-80. PubMed ID: 14768052
    [Abstract] [Full Text] [Related]

  • 40. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.
    Martins I, Deshayes F, Baton F, Forget A, Ciechomska I, Sylla K, Aoudjit F, Charron D, Al-Daccak R, Alcaide-Loridan C.
    Eur J Immunol; 2007 Mar 21; 37(3):788-97. PubMed ID: 17304627
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.